Parenteral cephalothin therapy for pelvic gonococcal infections.
The efficacy of intravenous cephalothin was studied prospectively in 20 patients with acute pelvic inflammatory disease, all of whom presented with lower abdominal pain, cervical and adnexal tenderness, fever, and leukocytosis. Blood, cervical, and cul-de-sac cultures were obtained on admission. The latter was transported anaerobically and inoculated in routine and prereduced medium. Transgrow medium with trimethoprim was used for endocervical cultures. Neisseria gonorrhoeae was isolated from the endocervix in 15 patients and from the cul-de-sac in four patients. All received intravenous cephalothin, 2 gm every four hours for seven days. Clinical improvement was observed in 48 to 78 hours. The cervical cultures were negative for N. gonorrhoeae after 48 hours, at the completion of treatment, and two weeks post-treatment. The drug was well tolerated. It was concluded that cephalothin intravenously is an acceptable alternative antibiotic for the treatment of gonococcal pelvic infection.
D002512:Cephalothin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D007263:Infusions, Parenteral; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy* / Q000209:etiology
D002512:Cephalothin